Cargando…

A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma

BACKGROUND: R849 is a neurovirulent γ(1)34.5 gene-deficient form of herpes simplex virus type 1 (HSV-1) and has LacZ genes at the deleted sites of the γ(1)34.5 gene. HF is a spontaneously occurring, fusogenic HSV-1 strain. The purpose of this work was to generate a virus that has the syncytial chara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takaoka, Hiroo, Takahashi, Gen, Ogawa, Fumi, Imai, Tomoaki, Iwai, Soichi, Yura, Yoshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131258/ https://www.ncbi.nlm.nih.gov/pubmed/21663640 http://dx.doi.org/10.1186/1743-422X-8-294

Ejemplares similares

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

Entry of Oncolytic Herpes Simplex Virus into Human Squamous Cell Carcinoma Cells by Ultrasound
por: Okunaga, Shusuke, et al.
Publicado: (2015)

Effect of ultrasound on herpes simplex virus infection in cell culture
por: Shintani, Motoko, et al.
Publicado: (2011)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Proteomic Analysis of Secretomes of Oncolytic Herpes Simplex Virus-Infected Squamous Cell Carcinoma Cells
por: Tada, Shinya, et al.
Publicado: (2018)

Involvement of intracellular free Ca(2+ )in enhanced release of herpes simplex virus by hydrogen peroxide
por: Arimoto, Emiko, et al.
Publicado: (2006)

Oncolytic virotherapy using herpes simplex virus: how far have we come?
por: Sokolowski, Nicolas AS, et al.
Publicado: (2015)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma
por: Krabbe, Teresa, et al.
Publicado: (2021)

Fusogenic Viruses in Oncolytic Immunotherapy
por: Krabbe, Teresa, et al.
Publicado: (2018)

ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Involvement of Hydrogen Peroxide in Safingol-Induced Endonuclease G-Mediated Apoptosis of Squamous Cell Carcinoma Cells
por: Hamada, Masakazu, et al.
Publicado: (2014)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023)

Structural basis for membrane anchoring and fusion regulation of the Herpes Simplex Virus fusogen gB
por: Cooper, Rebecca S., et al.
Publicado: (2018)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chen, Chun-Yu, et al.
Publicado: (2017)

Neuroblastomas Vary Widely in Their Sensitivities to Herpes Simplex Virotherapy Unrelated to Virus Receptors and Susceptibility
por: Wang, Pin-Yi, et al.
Publicado: (2015)

Measles virus: Background and oncolytic virotherapy
por: Bhattacharjee, Sankhajit, et al.
Publicado: (2018)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Oncolytic virotherapy – in vivo veritas
por: Kemler, Iris, et al.
Publicado: (2018)

Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020)

Delivery and Biosafety of Oncolytic Virotherapy
por: Li, Lizhi, et al.
Publicado: (2020)

Syncytia Formation in Oncolytic Virotherapy
por: Burton, Chase, et al.
Publicado: (2019)

Progress of oncolytic virotherapy for neuroblastoma
por: Chen, Xiao-Tong, et al.
Publicado: (2022)

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice
por: Israyelyan, Anna, et al.
Publicado: (2008)

Autophagy as a Survival Mechanism for Squamous Cell Carcinoma Cells in Endonuclease G-Mediated Apoptosis
por: Masui, Atsushi, et al.
Publicado: (2016)

Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma
por: Luo, Yong, et al.
Publicado: (2019)

A surface pocket in the cytoplasmic domain of the herpes simplex virus fusogen gB controls membrane fusion
por: Pataki, Zemplen, et al.
Publicado: (2022)

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy
por: Enow, Junior A., et al.
Publicado: (2023)

Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021)

Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
por: Scanlan, Hayle, et al.
Publicado: (2022)

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
por: Hu, Mingming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jlln0nbhor4mmbc72b1eojop7n